Zepbound has been approved as the new powerful treatment option for patients with obesity, overweight or weight related medical problems.
Although obesity is a chronic but treatable disease , people who have it are faced with lots of health and weight challenges and criticism daily.
Lilly’s Zepbound is reportedly the only first and approved treatment that activates two incretin hormone receptors GIP & GIP-1 to fight hidden causes of obesity.
Zepbound is expected to be available in the U.S. by the end of the year in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) at a list price of $1,059.87, which is approximately 20% lower than semaglutide 2.4 mg injection for weight loss.
NOTE : The newly approved drug also has some side effects that should be looked into by patients before consumption.